ZymoGenetics Presents Positive Results From RECOTHROM(TM) Thrombin, Topical (Recombinant) Spray Study In Burn Patients
ZymoGenetics, Inc. (NASDAQ:ZGEN), presented results at the American Burn Association annual meeting from a clinical trial with RECOTHROM™ Thrombin, topical (Recombinant) administered by spray device to burn wound excision sites. The study evaluated the safety and immunogenicity of RECOTHROM for patients undergoing skin grafting for burns.
This post is an original post by ScienceDaily: Skin Care News
Posted: May 2nd, 2008 under skin health.
Comments: none
Write a comment